nodes	percent_of_prediction	percent_of_DWPC	metapath
Vismodegib—skin cancer—sarcoma	0.634	1	CtDrD
Vismodegib—ABCG2—Dactinomycin—sarcoma	0.0414	0.167	CbGbCtD
Vismodegib—ABCG2—Mitoxantrone—sarcoma	0.0371	0.149	CbGbCtD
Vismodegib—ABCG2—Vincristine—sarcoma	0.0255	0.103	CbGbCtD
Vismodegib—ABCG2—Etoposide—sarcoma	0.0234	0.0942	CbGbCtD
Vismodegib—CYP3A4—Thiotepa—sarcoma	0.0186	0.0751	CbGbCtD
Vismodegib—ABCG2—Doxorubicin—sarcoma	0.0159	0.0643	CbGbCtD
Vismodegib—ABCB1—Dactinomycin—sarcoma	0.0149	0.0602	CbGbCtD
Vismodegib—ABCB1—Mitoxantrone—sarcoma	0.0134	0.0539	CbGbCtD
Vismodegib—CYP2C8—Etoposide—sarcoma	0.0125	0.0502	CbGbCtD
Vismodegib—ABCB1—Vincristine—sarcoma	0.0092	0.0371	CbGbCtD
Vismodegib—ABCB1—Etoposide—sarcoma	0.00843	0.034	CbGbCtD
Vismodegib—CYP3A4—Mitoxantrone—sarcoma	0.00801	0.0323	CbGbCtD
Vismodegib—SHH—skull—sarcoma	0.00741	0.161	CbGeAlD
Vismodegib—SHH—forelimb—sarcoma	0.00713	0.155	CbGeAlD
Vismodegib—ABCB1—Doxorubicin—sarcoma	0.00575	0.0232	CbGbCtD
Vismodegib—CYP3A4—Vincristine—sarcoma	0.00551	0.0222	CbGbCtD
Vismodegib—SHH—appendage—sarcoma	0.0055	0.12	CbGeAlD
Vismodegib—CYP3A4—Etoposide—sarcoma	0.00505	0.0204	CbGbCtD
Vismodegib—CYP3A4—Doxorubicin—sarcoma	0.00344	0.0139	CbGbCtD
Vismodegib—Menopause—Thiotepa—sarcoma	0.00281	0.0585	CcSEcCtD
Vismodegib—Potassium low—Mitoxantrone—sarcoma	0.00263	0.0547	CcSEcCtD
Vismodegib—SHH—Ectoderm Differentiation—PTPRB—sarcoma	0.00208	0.107	CbGpPWpGaD
Vismodegib—SMO—mammary gland—sarcoma	0.00187	0.0407	CbGeAlD
Vismodegib—SHH—embryo—sarcoma	0.00183	0.0397	CbGeAlD
Vismodegib—SHH—connective tissue—sarcoma	0.00157	0.0342	CbGeAlD
Vismodegib—Blood potassium decreased—Mitoxantrone—sarcoma	0.00145	0.0302	CcSEcCtD
Vismodegib—SHH—skin of body—sarcoma	0.00142	0.0308	CbGeAlD
Vismodegib—SHH—FOXA1 transcription factor network—COL18A1—sarcoma	0.00141	0.0725	CbGpPWpGaD
Vismodegib—SMO—myometrium—sarcoma	0.00133	0.0289	CbGeAlD
Vismodegib—SMO—embryo—sarcoma	0.00128	0.0278	CbGeAlD
Vismodegib—SMO—seminal vesicle—sarcoma	0.0012	0.0261	CbGeAlD
Vismodegib—Sorafenib—FLT1—sarcoma	0.00112	0.26	CrCbGaD
Vismodegib—SMO—connective tissue—sarcoma	0.0011	0.0239	CbGeAlD
Vismodegib—SHH—Heart Development—VEGFC—sarcoma	0.00107	0.0549	CbGpPWpGaD
Vismodegib—Azotaemia—Vincristine—sarcoma	0.00106	0.0221	CcSEcCtD
Vismodegib—SHH—bone marrow—sarcoma	0.00105	0.0227	CbGeAlD
Vismodegib—SMO—skin of body—sarcoma	0.000992	0.0216	CbGeAlD
Vismodegib—Sorafenib—PDGFRB—sarcoma	0.000924	0.215	CrCbGaD
Vismodegib—Sorafenib—PDGFRA—sarcoma	0.0009	0.209	CrCbGaD
Vismodegib—SMO—cardiac atrium—sarcoma	0.000866	0.0188	CbGeAlD
Vismodegib—SMO—uterus—sarcoma	0.000862	0.0187	CbGeAlD
Vismodegib—SHH—Ectoderm Differentiation—PAX3—sarcoma	0.000862	0.0444	CbGpPWpGaD
Vismodegib—SMO—tendon—sarcoma	0.000755	0.0164	CbGeAlD
Vismodegib—Neoplasm malignant—Thiotepa—sarcoma	0.000747	0.0155	CcSEcCtD
Vismodegib—Amenorrhoea—Thiotepa—sarcoma	0.000726	0.0151	CcSEcCtD
Vismodegib—ALB—mammary gland—sarcoma	0.000718	0.0156	CbGeAlD
Vismodegib—Sorafenib—KDR—sarcoma	0.0007	0.163	CrCbGaD
Vismodegib—Musculoskeletal chest pain—Epirubicin—sarcoma	0.000663	0.0138	CcSEcCtD
Vismodegib—Sorafenib—KIT—sarcoma	0.000661	0.154	CrCbGaD
Vismodegib—Amenorrhoea—Mitoxantrone—sarcoma	0.000627	0.013	CcSEcCtD
Vismodegib—SMO—testis—sarcoma	0.000625	0.0136	CbGeAlD
Vismodegib—Musculoskeletal chest pain—Doxorubicin—sarcoma	0.000613	0.0128	CcSEcCtD
Vismodegib—Blood urea increased—Thiotepa—sarcoma	0.000602	0.0125	CcSEcCtD
Vismodegib—SMO—liver—sarcoma	0.000591	0.0129	CbGeAlD
Vismodegib—Hepatic enzyme increased—Mitoxantrone—sarcoma	0.000583	0.0121	CcSEcCtD
Vismodegib—Musculoskeletal pain—Vincristine—sarcoma	0.000573	0.0119	CcSEcCtD
Vismodegib—Blood alkaline phosphatase increased—Thiotepa—sarcoma	0.000532	0.0111	CcSEcCtD
Vismodegib—Blood urea increased—Mitoxantrone—sarcoma	0.00052	0.0108	CcSEcCtD
Vismodegib—CYP2C8—mammary gland—sarcoma	0.000504	0.011	CbGeAlD
Vismodegib—ORM1—hematopoietic system—sarcoma	0.000499	0.0108	CbGeAlD
Vismodegib—Phosphatase alkaline increased—Etoposide—sarcoma	0.000458	0.00954	CcSEcCtD
Vismodegib—SMO—lymph node—sarcoma	0.000453	0.00986	CbGeAlD
Vismodegib—CYP2C9—mammary gland—sarcoma	0.000448	0.00974	CbGeAlD
Vismodegib—Dehydration—Thiotepa—sarcoma	0.000431	0.00896	CcSEcCtD
Vismodegib—SHH—Differentiation Pathway—KIT—sarcoma	0.000422	0.0218	CbGpPWpGaD
Vismodegib—Aspartate aminotransferase increased—Thiotepa—sarcoma	0.000417	0.00868	CcSEcCtD
Vismodegib—Aspartate aminotransferase increased—Dactinomycin—sarcoma	0.000414	0.00861	CcSEcCtD
Vismodegib—Hyponatraemia—Vincristine—sarcoma	0.000412	0.00858	CcSEcCtD
Vismodegib—Pain in extremity—Vincristine—sarcoma	0.000411	0.00855	CcSEcCtD
Vismodegib—Hyponatraemia—Mitoxantrone—sarcoma	0.000402	0.00836	CcSEcCtD
Vismodegib—Blood alkaline phosphatase increased—Etoposide—sarcoma	0.000382	0.00796	CcSEcCtD
Vismodegib—ALB—Scavenging of heme from plasma—HBA1—sarcoma	0.000382	0.0197	CbGpPWpGaD
Vismodegib—Dehydration—Vincristine—sarcoma	0.000382	0.00795	CcSEcCtD
Vismodegib—Dehydration—Mitoxantrone—sarcoma	0.000372	0.00774	CcSEcCtD
Vismodegib—Aspartate aminotransferase increased—Vincristine—sarcoma	0.00037	0.0077	CcSEcCtD
Vismodegib—Abdominal pain upper—Mitoxantrone—sarcoma	0.000365	0.0076	CcSEcCtD
Vismodegib—Hypokalaemia—Mitoxantrone—sarcoma	0.000364	0.00757	CcSEcCtD
Vismodegib—Aspartate aminotransferase increased—Mitoxantrone—sarcoma	0.00036	0.00749	CcSEcCtD
Vismodegib—CYP2C19—hematopoietic system—sarcoma	0.000352	0.00766	CbGeAlD
Vismodegib—ABCG2—myometrium—sarcoma	0.000348	0.00757	CbGeAlD
Vismodegib—SHH—Integrated Pancreatic Cancer Pathway—WT1—sarcoma	0.00034	0.0175	CbGpPWpGaD
Vismodegib—SMO—Integrated Pancreatic Cancer Pathway—WT1—sarcoma	0.000322	0.0166	CbGpPWpGaD
Vismodegib—Weight decreased—Vincristine—sarcoma	0.000321	0.00668	CcSEcCtD
Vismodegib—ORM1—bone marrow—sarcoma	0.00032	0.00695	CbGeAlD
Vismodegib—SHH—Hair Follicle Development: Induction (Part 1 of 3)—CTNNB1—sarcoma	0.000319	0.0165	CbGpPWpGaD
Vismodegib—Ageusia—Epirubicin—sarcoma	0.000317	0.0066	CcSEcCtD
Vismodegib—Connective tissue disorder—Thiotepa—sarcoma	0.000315	0.00655	CcSEcCtD
Vismodegib—ABCG2—seminal vesicle—sarcoma	0.000314	0.00684	CbGeAlD
Vismodegib—Weight decreased—Mitoxantrone—sarcoma	0.000313	0.00651	CcSEcCtD
Vismodegib—SHH—FOXA1 transcription factor network—JUN—sarcoma	0.00031	0.016	CbGpPWpGaD
Vismodegib—SHH—Heart Development—CTNNB1—sarcoma	0.000308	0.0159	CbGpPWpGaD
Vismodegib—CYP2C8—hematopoietic system—sarcoma	0.000307	0.00668	CbGeAlD
Vismodegib—SHH—Validated transcriptional targets of TAp63 isoforms—MDM2—sarcoma	0.000303	0.0156	CbGpPWpGaD
Vismodegib—SMO—Hair Follicle Development: Induction (Part 1 of 3)—CTNNB1—sarcoma	0.000303	0.0156	CbGpPWpGaD
Vismodegib—Neoplasm malignant—Epirubicin—sarcoma	0.000301	0.00626	CcSEcCtD
Vismodegib—Ageusia—Doxorubicin—sarcoma	0.000293	0.00611	CcSEcCtD
Vismodegib—Amenorrhoea—Epirubicin—sarcoma	0.000292	0.00608	CcSEcCtD
Vismodegib—Alopecia—Thiotepa—sarcoma	0.000283	0.00589	CcSEcCtD
Vismodegib—Alopecia—Dactinomycin—sarcoma	0.000281	0.00585	CcSEcCtD
Vismodegib—Connective tissue disorder—Vincristine—sarcoma	0.000279	0.00581	CcSEcCtD
Vismodegib—Malnutrition—Thiotepa—sarcoma	0.000279	0.0058	CcSEcCtD
Vismodegib—Neoplasm malignant—Doxorubicin—sarcoma	0.000278	0.00579	CcSEcCtD
Vismodegib—CYP2C9—hematopoietic system—sarcoma	0.000273	0.00594	CbGeAlD
Vismodegib—SHH—Heart Development—VEGFA—sarcoma	0.000271	0.014	CbGpPWpGaD
Vismodegib—Amenorrhoea—Doxorubicin—sarcoma	0.000271	0.00563	CcSEcCtD
Vismodegib—Back pain—Thiotepa—sarcoma	0.00027	0.00561	CcSEcCtD
Vismodegib—Musculoskeletal pain—Epirubicin—sarcoma	0.00026	0.00541	CcSEcCtD
Vismodegib—SHH—Hair Follicle Development: Induction (Part 1 of 3)—MYC—sarcoma	0.000259	0.0133	CbGpPWpGaD
Vismodegib—ORM1—liver—sarcoma	0.000258	0.00562	CbGeAlD
Vismodegib—Phosphatase alkaline increased—Epirubicin—sarcoma	0.000257	0.00535	CcSEcCtD
Vismodegib—SHH—Hair Follicle Development: Induction (Part 1 of 3)—EGFR—sarcoma	0.000253	0.013	CbGpPWpGaD
Vismodegib—SHH—Differentiation Pathway—VEGFA—sarcoma	0.000253	0.013	CbGpPWpGaD
Vismodegib—Alopecia—Vincristine—sarcoma	0.000251	0.00522	CcSEcCtD
Vismodegib—ABCG2—HIF-2-alpha transcription factor network—FLT1—sarcoma	0.000249	0.0128	CbGpPWpGaD
Vismodegib—SMO—Hair Follicle Development: Induction (Part 1 of 3)—MYC—sarcoma	0.000245	0.0126	CbGpPWpGaD
Vismodegib—Alopecia—Mitoxantrone—sarcoma	0.000245	0.00509	CcSEcCtD
Vismodegib—Blood urea increased—Epirubicin—sarcoma	0.000243	0.00505	CcSEcCtD
Vismodegib—Musculoskeletal pain—Doxorubicin—sarcoma	0.000241	0.00501	CcSEcCtD
Vismodegib—SMO—Hair Follicle Development: Induction (Part 1 of 3)—EGFR—sarcoma	0.00024	0.0124	CbGpPWpGaD
Vismodegib—ALB—testis—sarcoma	0.00024	0.00521	CbGeAlD
Vismodegib—Back pain—Vincristine—sarcoma	0.000239	0.00498	CcSEcCtD
Vismodegib—Phosphatase alkaline increased—Doxorubicin—sarcoma	0.000238	0.00495	CcSEcCtD
Vismodegib—Arthralgia—Thiotepa—sarcoma	0.000237	0.00494	CcSEcCtD
Vismodegib—Myalgia—Thiotepa—sarcoma	0.000237	0.00494	CcSEcCtD
Vismodegib—Dysgeusia—Mitoxantrone—sarcoma	0.000236	0.00491	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—sarcoma	0.000236	0.00491	CcSEcCtD
Vismodegib—Myalgia—Dactinomycin—sarcoma	0.000236	0.0049	CcSEcCtD
Vismodegib—Back pain—Mitoxantrone—sarcoma	0.000233	0.00485	CcSEcCtD
Vismodegib—ABCG2—Fluoropyrimidine Activity—SMUG1—sarcoma	0.000231	0.0119	CbGpPWpGaD
Vismodegib—ALB—liver—sarcoma	0.000227	0.00493	CbGeAlD
Vismodegib—ABCG2—uterus—sarcoma	0.000226	0.00491	CbGeAlD
Vismodegib—Blood urea increased—Doxorubicin—sarcoma	0.000224	0.00467	CcSEcCtD
Vismodegib—Nervous system disorder—Thiotepa—sarcoma	0.000223	0.00465	CcSEcCtD
Vismodegib—Skin disorder—Thiotepa—sarcoma	0.000221	0.0046	CcSEcCtD
Vismodegib—Blood alkaline phosphatase increased—Epirubicin—sarcoma	0.000214	0.00446	CcSEcCtD
Vismodegib—Myalgia—Vincristine—sarcoma	0.000211	0.00438	CcSEcCtD
Vismodegib—CYP3A4—hematopoietic system—sarcoma	0.000208	0.00453	CbGeAlD
Vismodegib—Musculoskeletal discomfort—Thiotepa—sarcoma	0.000207	0.00432	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Dactinomycin—sarcoma	0.000206	0.00428	CcSEcCtD
Vismodegib—Myalgia—Mitoxantrone—sarcoma	0.000205	0.00427	CcSEcCtD
Vismodegib—Arthralgia—Mitoxantrone—sarcoma	0.000205	0.00427	CcSEcCtD
Vismodegib—Alopecia—Etoposide—sarcoma	0.000203	0.00423	CcSEcCtD
Vismodegib—Dyspepsia—Thiotepa—sarcoma	0.0002	0.00417	CcSEcCtD
Vismodegib—Blood alkaline phosphatase increased—Doxorubicin—sarcoma	0.000198	0.00413	CcSEcCtD
Vismodegib—ORM1—lymph node—sarcoma	0.000198	0.00431	CbGeAlD
Vismodegib—Nervous system disorder—Vincristine—sarcoma	0.000198	0.00412	CcSEcCtD
Vismodegib—Decreased appetite—Thiotepa—sarcoma	0.000198	0.00412	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Thiotepa—sarcoma	0.000197	0.00409	CcSEcCtD
Vismodegib—Decreased appetite—Dactinomycin—sarcoma	0.000196	0.00409	CcSEcCtD
Vismodegib—Fatigue—Thiotepa—sarcoma	0.000196	0.00408	CcSEcCtD
Vismodegib—Dysgeusia—Etoposide—sarcoma	0.000196	0.00408	CcSEcCtD
Vismodegib—ABCG2—HIF-1-alpha transcription factor network—NPM1—sarcoma	0.000196	0.0101	CbGpPWpGaD
Vismodegib—Fatigue—Dactinomycin—sarcoma	0.000195	0.00405	CcSEcCtD
Vismodegib—Constipation—Thiotepa—sarcoma	0.000195	0.00405	CcSEcCtD
Vismodegib—Pain—Thiotepa—sarcoma	0.000195	0.00405	CcSEcCtD
Vismodegib—Back pain—Etoposide—sarcoma	0.000194	0.00403	CcSEcCtD
Vismodegib—Pain—Dactinomycin—sarcoma	0.000193	0.00402	CcSEcCtD
Vismodegib—Muscle spasms—Etoposide—sarcoma	0.000193	0.00401	CcSEcCtD
Vismodegib—ABCG2—bone marrow—sarcoma	0.000192	0.00416	CbGeAlD
Vismodegib—Skin disorder—Mitoxantrone—sarcoma	0.000191	0.00397	CcSEcCtD
Vismodegib—Hyponatraemia—Epirubicin—sarcoma	0.000187	0.0039	CcSEcCtD
Vismodegib—Pain in extremity—Epirubicin—sarcoma	0.000186	0.00388	CcSEcCtD
Vismodegib—Gastrointestinal pain—Thiotepa—sarcoma	0.000186	0.00387	CcSEcCtD
Vismodegib—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—FLT1—sarcoma	0.000186	0.00959	CbGpPWpGaD
Vismodegib—Gastrointestinal pain—Dactinomycin—sarcoma	0.000185	0.00384	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Vincristine—sarcoma	0.000184	0.00383	CcSEcCtD
Vismodegib—CYP2C19—liver—sarcoma	0.000182	0.00397	CbGeAlD
Vismodegib—SHH—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	0.00018	0.0093	CbGpPWpGaD
Vismodegib—Abdominal pain—Thiotepa—sarcoma	0.00018	0.00374	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Mitoxantrone—sarcoma	0.000179	0.00373	CcSEcCtD
Vismodegib—Abdominal pain—Dactinomycin—sarcoma	0.000179	0.00372	CcSEcCtD
Vismodegib—Decreased appetite—Vincristine—sarcoma	0.000175	0.00365	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Vincristine—sarcoma	0.000174	0.00363	CcSEcCtD
Vismodegib—Fatigue—Vincristine—sarcoma	0.000174	0.00362	CcSEcCtD
Vismodegib—ALB—lymph node—sarcoma	0.000174	0.00378	CbGeAlD
Vismodegib—Dehydration—Epirubicin—sarcoma	0.000173	0.00361	CcSEcCtD
Vismodegib—Hyponatraemia—Doxorubicin—sarcoma	0.000173	0.0036	CcSEcCtD
Vismodegib—Dyspepsia—Mitoxantrone—sarcoma	0.000173	0.0036	CcSEcCtD
Vismodegib—Pain—Vincristine—sarcoma	0.000173	0.00359	CcSEcCtD
Vismodegib—Constipation—Vincristine—sarcoma	0.000173	0.00359	CcSEcCtD
Vismodegib—Pain in extremity—Doxorubicin—sarcoma	0.000173	0.00359	CcSEcCtD
Vismodegib—ABCB1—myometrium—sarcoma	0.000172	0.00373	CbGeAlD
Vismodegib—SMO—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	0.000171	0.00882	CbGpPWpGaD
Vismodegib—Decreased appetite—Mitoxantrone—sarcoma	0.000171	0.00356	CcSEcCtD
Vismodegib—Abdominal pain upper—Epirubicin—sarcoma	0.00017	0.00354	CcSEcCtD
Vismodegib—Hypokalaemia—Epirubicin—sarcoma	0.00017	0.00353	CcSEcCtD
Vismodegib—Fatigue—Mitoxantrone—sarcoma	0.000169	0.00353	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—sarcoma	0.000169	0.00352	CcSEcCtD
Vismodegib—Breast disorder—Epirubicin—sarcoma	0.000169	0.00351	CcSEcCtD
Vismodegib—CYP2C8—testis—sarcoma	0.000168	0.00366	CbGeAlD
Vismodegib—Pain—Mitoxantrone—sarcoma	0.000168	0.0035	CcSEcCtD
Vismodegib—Constipation—Mitoxantrone—sarcoma	0.000168	0.0035	CcSEcCtD
Vismodegib—Aspartate aminotransferase increased—Epirubicin—sarcoma	0.000168	0.00349	CcSEcCtD
Vismodegib—Gastrointestinal pain—Vincristine—sarcoma	0.000165	0.00343	CcSEcCtD
Vismodegib—ABCB1—embryo—sarcoma	0.000165	0.00359	CbGeAlD
Vismodegib—ABCG2—testis—sarcoma	0.000164	0.00356	CbGeAlD
Vismodegib—Asthenia—Thiotepa—sarcoma	0.000163	0.0034	CcSEcCtD
Vismodegib—Asthenia—Dactinomycin—sarcoma	0.000162	0.00337	CcSEcCtD
Vismodegib—Pruritus—Thiotepa—sarcoma	0.000161	0.00335	CcSEcCtD
Vismodegib—Gastrointestinal pain—Mitoxantrone—sarcoma	0.000161	0.00334	CcSEcCtD
Vismodegib—Dehydration—Doxorubicin—sarcoma	0.00016	0.00334	CcSEcCtD
Vismodegib—Abdominal pain—Vincristine—sarcoma	0.00016	0.00332	CcSEcCtD
Vismodegib—CYP2C8—liver—sarcoma	0.000159	0.00346	CbGeAlD
Vismodegib—Skin disorder—Etoposide—sarcoma	0.000159	0.0033	CcSEcCtD
Vismodegib—Abdominal pain upper—Doxorubicin—sarcoma	0.000158	0.00328	CcSEcCtD
Vismodegib—Hypokalaemia—Doxorubicin—sarcoma	0.000157	0.00327	CcSEcCtD
Vismodegib—Breast disorder—Doxorubicin—sarcoma	0.000156	0.00324	CcSEcCtD
Vismodegib—Diarrhoea—Thiotepa—sarcoma	0.000156	0.00324	CcSEcCtD
Vismodegib—Abdominal pain—Mitoxantrone—sarcoma	0.000155	0.00323	CcSEcCtD
Vismodegib—Aspartate aminotransferase increased—Doxorubicin—sarcoma	0.000155	0.00323	CcSEcCtD
Vismodegib—ABCB1—seminal vesicle—sarcoma	0.000155	0.00337	CbGeAlD
Vismodegib—ABCG2—liver—sarcoma	0.000155	0.00337	CbGeAlD
Vismodegib—Diarrhoea—Dactinomycin—sarcoma	0.000155	0.00322	CcSEcCtD
Vismodegib—ALB—Binding and Uptake of Ligands by Scavenger Receptors—HBA1—sarcoma	0.000152	0.00786	CbGpPWpGaD
Vismodegib—ABCB1—hematopoietic system—sarcoma	0.000147	0.0032	CbGeAlD
Vismodegib—Weight decreased—Epirubicin—sarcoma	0.000146	0.00303	CcSEcCtD
Vismodegib—Asthenia—Vincristine—sarcoma	0.000145	0.00301	CcSEcCtD
Vismodegib—Vomiting—Thiotepa—sarcoma	0.000145	0.00301	CcSEcCtD
Vismodegib—ABCG2—HIF-2-alpha transcription factor network—KDR—sarcoma	0.000144	0.00741	CbGpPWpGaD
Vismodegib—Vomiting—Dactinomycin—sarcoma	0.000144	0.00299	CcSEcCtD
Vismodegib—Rash—Thiotepa—sarcoma	0.000144	0.00299	CcSEcCtD
Vismodegib—Dermatitis—Thiotepa—sarcoma	0.000143	0.00298	CcSEcCtD
Vismodegib—Rash—Dactinomycin—sarcoma	0.000142	0.00296	CcSEcCtD
Vismodegib—Decreased appetite—Etoposide—sarcoma	0.000142	0.00296	CcSEcCtD
Vismodegib—CYP2C9—liver—sarcoma	0.000141	0.00307	CbGeAlD
Vismodegib—Gastrointestinal disorder—Etoposide—sarcoma	0.000141	0.00294	CcSEcCtD
Vismodegib—Asthenia—Mitoxantrone—sarcoma	0.000141	0.00293	CcSEcCtD
Vismodegib—Fatigue—Etoposide—sarcoma	0.000141	0.00293	CcSEcCtD
Vismodegib—Pain—Etoposide—sarcoma	0.00014	0.00291	CcSEcCtD
Vismodegib—Constipation—Etoposide—sarcoma	0.00014	0.00291	CcSEcCtD
Vismodegib—ABCG2—HIF-1-alpha transcription factor network—CXCR4—sarcoma	0.000138	0.00714	CbGpPWpGaD
Vismodegib—Diarrhoea—Vincristine—sarcoma	0.000138	0.00287	CcSEcCtD
Vismodegib—Nausea—Thiotepa—sarcoma	0.000135	0.00281	CcSEcCtD
Vismodegib—Weight decreased—Doxorubicin—sarcoma	0.000135	0.00281	CcSEcCtD
Vismodegib—Diarrhoea—Mitoxantrone—sarcoma	0.000134	0.0028	CcSEcCtD
Vismodegib—Nausea—Dactinomycin—sarcoma	0.000134	0.00279	CcSEcCtD
Vismodegib—Gastrointestinal pain—Etoposide—sarcoma	0.000134	0.00278	CcSEcCtD
Vismodegib—SHH—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	0.000133	0.00687	CbGpPWpGaD
Vismodegib—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRB—sarcoma	0.00013	0.00668	CbGpPWpGaD
Vismodegib—Abdominal pain—Etoposide—sarcoma	0.000129	0.00269	CcSEcCtD
Vismodegib—Vomiting—Vincristine—sarcoma	0.000128	0.00267	CcSEcCtD
Vismodegib—ALB—Vitamin B12 Metabolism—HBA1—sarcoma	0.000128	0.0066	CbGpPWpGaD
Vismodegib—SHH—GPCR ligand binding—CXCR4—sarcoma	0.000128	0.00657	CbGpPWpGaD
Vismodegib—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRA—sarcoma	0.000128	0.00657	CbGpPWpGaD
Vismodegib—Rash—Vincristine—sarcoma	0.000127	0.00265	CcSEcCtD
Vismodegib—Dermatitis—Vincristine—sarcoma	0.000127	0.00265	CcSEcCtD
Vismodegib—Connective tissue disorder—Epirubicin—sarcoma	0.000127	0.00264	CcSEcCtD
Vismodegib—SMO—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	0.000126	0.00651	CbGpPWpGaD
Vismodegib—Vomiting—Mitoxantrone—sarcoma	0.000125	0.0026	CcSEcCtD
Vismodegib—Rash—Mitoxantrone—sarcoma	0.000124	0.00258	CcSEcCtD
Vismodegib—Dermatitis—Mitoxantrone—sarcoma	0.000124	0.00258	CcSEcCtD
Vismodegib—SHH—Ectoderm Differentiation—CTNNB1—sarcoma	0.000123	0.00635	CbGpPWpGaD
Vismodegib—SMO—GPCR ligand binding—CXCR4—sarcoma	0.000121	0.00623	CbGpPWpGaD
Vismodegib—Nausea—Vincristine—sarcoma	0.00012	0.00249	CcSEcCtD
Vismodegib—ABCG2—lymph node—sarcoma	0.000119	0.00258	CbGeAlD
Vismodegib—Asthenia—Etoposide—sarcoma	0.000117	0.00244	CcSEcCtD
Vismodegib—Connective tissue disorder—Doxorubicin—sarcoma	0.000117	0.00244	CcSEcCtD
Vismodegib—Nausea—Mitoxantrone—sarcoma	0.000117	0.00243	CcSEcCtD
Vismodegib—Pruritus—Etoposide—sarcoma	0.000116	0.00241	CcSEcCtD
Vismodegib—Alopecia—Epirubicin—sarcoma	0.000114	0.00237	CcSEcCtD
Vismodegib—Malnutrition—Epirubicin—sarcoma	0.000112	0.00234	CcSEcCtD
Vismodegib—Diarrhoea—Etoposide—sarcoma	0.000112	0.00233	CcSEcCtD
Vismodegib—ABCB1—uterus—sarcoma	0.000111	0.00242	CbGeAlD
Vismodegib—SHH—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	0.00011	0.00568	CbGpPWpGaD
Vismodegib—Dysgeusia—Epirubicin—sarcoma	0.00011	0.00229	CcSEcCtD
Vismodegib—CYP2C19—Melatonin metabolism and effects—FOXO1—sarcoma	0.000109	0.00564	CbGpPWpGaD
Vismodegib—Back pain—Epirubicin—sarcoma	0.000109	0.00226	CcSEcCtD
Vismodegib—Muscle spasms—Epirubicin—sarcoma	0.000108	0.00225	CcSEcCtD
Vismodegib—CYP3A4—liver—sarcoma	0.000108	0.00234	CbGeAlD
Vismodegib—ABCB1—HIF-1-alpha transcription factor network—NPM1—sarcoma	0.000106	0.00546	CbGpPWpGaD
Vismodegib—Alopecia—Doxorubicin—sarcoma	0.000105	0.00219	CcSEcCtD
Vismodegib—SMO—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	0.000104	0.00538	CbGpPWpGaD
Vismodegib—ALB—Folate Metabolism—HBA1—sarcoma	0.000104	0.00537	CbGpPWpGaD
Vismodegib—Vomiting—Etoposide—sarcoma	0.000104	0.00216	CcSEcCtD
Vismodegib—Malnutrition—Doxorubicin—sarcoma	0.000104	0.00216	CcSEcCtD
Vismodegib—ABCB1—lymphoid tissue—sarcoma	0.000104	0.00226	CbGeAlD
Vismodegib—Rash—Etoposide—sarcoma	0.000103	0.00215	CcSEcCtD
Vismodegib—Dermatitis—Etoposide—sarcoma	0.000103	0.00214	CcSEcCtD
Vismodegib—Dysgeusia—Doxorubicin—sarcoma	0.000102	0.00212	CcSEcCtD
Vismodegib—CYP2C19—Constitutive Androstane Receptor Pathway—FOXO1—sarcoma	0.000101	0.00521	CbGpPWpGaD
Vismodegib—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—FLT1—sarcoma	0.000101	0.00519	CbGpPWpGaD
Vismodegib—Back pain—Doxorubicin—sarcoma	0.000101	0.00209	CcSEcCtD
Vismodegib—Muscle spasms—Doxorubicin—sarcoma	9.99e-05	0.00208	CcSEcCtD
Vismodegib—SHH—Ectoderm Differentiation—MYC—sarcoma	9.99e-05	0.00515	CbGpPWpGaD
Vismodegib—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—sarcoma	9.89e-05	0.0051	CbGpPWpGaD
Vismodegib—ABCB1—Constitutive Androstane Receptor Pathway—FOXO1—sarcoma	9.87e-05	0.00509	CbGpPWpGaD
Vismodegib—Nausea—Etoposide—sarcoma	9.71e-05	0.00202	CcSEcCtD
Vismodegib—ALB—Platelet degranulation—VEGFC—sarcoma	9.7e-05	0.005	CbGpPWpGaD
Vismodegib—SHH—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	9.6e-05	0.00495	CbGpPWpGaD
Vismodegib—SHH—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	9.58e-05	0.00494	CbGpPWpGaD
Vismodegib—Arthralgia—Epirubicin—sarcoma	9.56e-05	0.00199	CcSEcCtD
Vismodegib—Myalgia—Epirubicin—sarcoma	9.56e-05	0.00199	CcSEcCtD
Vismodegib—SHH—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	9.51e-05	0.0049	CbGpPWpGaD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	9.5e-05	0.00198	CcSEcCtD
Vismodegib—ABCB1—bone marrow—sarcoma	9.45e-05	0.00205	CbGeAlD
Vismodegib—ALB—Response to elevated platelet cytosolic Ca2+—VEGFC—sarcoma	9.24e-05	0.00476	CbGpPWpGaD
Vismodegib—CYP2C9—Constitutive Androstane Receptor Pathway—FOXO1—sarcoma	9.22e-05	0.00475	CbGpPWpGaD
Vismodegib—SMO—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	9.1e-05	0.00469	CbGpPWpGaD
Vismodegib—SMO—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	9.08e-05	0.00468	CbGpPWpGaD
Vismodegib—SMO—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	9.01e-05	0.00464	CbGpPWpGaD
Vismodegib—Nervous system disorder—Epirubicin—sarcoma	8.99e-05	0.00187	CcSEcCtD
Vismodegib—Skin disorder—Epirubicin—sarcoma	8.9e-05	0.00185	CcSEcCtD
Vismodegib—Arthralgia—Doxorubicin—sarcoma	8.85e-05	0.00184	CcSEcCtD
Vismodegib—Myalgia—Doxorubicin—sarcoma	8.85e-05	0.00184	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	8.79e-05	0.00183	CcSEcCtD
Vismodegib—SHH—Disease—TLE1—sarcoma	8.67e-05	0.00447	CbGpPWpGaD
Vismodegib—SHH—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	8.59e-05	0.00443	CbGpPWpGaD
Vismodegib—SHH—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	8.37e-05	0.00431	CbGpPWpGaD
Vismodegib—Musculoskeletal discomfort—Epirubicin—sarcoma	8.35e-05	0.00174	CcSEcCtD
Vismodegib—Nervous system disorder—Doxorubicin—sarcoma	8.32e-05	0.00173	CcSEcCtD
Vismodegib—ALB—Selenium Micronutrient Network—HBA1—sarcoma	8.27e-05	0.00426	CbGpPWpGaD
Vismodegib—Skin disorder—Doxorubicin—sarcoma	8.24e-05	0.00171	CcSEcCtD
Vismodegib—SMO—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	8.15e-05	0.0042	CbGpPWpGaD
Vismodegib—ABCB1—testis—sarcoma	8.07e-05	0.00176	CbGeAlD
Vismodegib—Dyspepsia—Epirubicin—sarcoma	8.07e-05	0.00168	CcSEcCtD
Vismodegib—Decreased appetite—Epirubicin—sarcoma	7.97e-05	0.00166	CcSEcCtD
Vismodegib—SMO—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	7.93e-05	0.00409	CbGpPWpGaD
Vismodegib—ABCG2—HIF-2-alpha transcription factor network—VEGFA—sarcoma	7.92e-05	0.00408	CbGpPWpGaD
Vismodegib—Gastrointestinal disorder—Epirubicin—sarcoma	7.91e-05	0.00165	CcSEcCtD
Vismodegib—Fatigue—Epirubicin—sarcoma	7.9e-05	0.00164	CcSEcCtD
Vismodegib—Pain—Epirubicin—sarcoma	7.84e-05	0.00163	CcSEcCtD
Vismodegib—Constipation—Epirubicin—sarcoma	7.84e-05	0.00163	CcSEcCtD
Vismodegib—SHH—Disease—NPM1—sarcoma	7.82e-05	0.00403	CbGpPWpGaD
Vismodegib—Musculoskeletal discomfort—Doxorubicin—sarcoma	7.73e-05	0.00161	CcSEcCtD
Vismodegib—SHH—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	7.7e-05	0.00397	CbGpPWpGaD
Vismodegib—ABCB1—liver—sarcoma	7.63e-05	0.00166	CbGeAlD
Vismodegib—SHH—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	7.53e-05	0.00388	CbGpPWpGaD
Vismodegib—Gastrointestinal pain—Epirubicin—sarcoma	7.49e-05	0.00156	CcSEcCtD
Vismodegib—ABCB1—HIF-1-alpha transcription factor network—CXCR4—sarcoma	7.49e-05	0.00386	CbGpPWpGaD
Vismodegib—Dyspepsia—Doxorubicin—sarcoma	7.47e-05	0.00155	CcSEcCtD
Vismodegib—ABCG2—HIF-1-alpha transcription factor network—CREB1—sarcoma	7.42e-05	0.00382	CbGpPWpGaD
Vismodegib—Decreased appetite—Doxorubicin—sarcoma	7.37e-05	0.00153	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Doxorubicin—sarcoma	7.32e-05	0.00152	CcSEcCtD
Vismodegib—Fatigue—Doxorubicin—sarcoma	7.31e-05	0.00152	CcSEcCtD
Vismodegib—SMO—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	7.3e-05	0.00376	CbGpPWpGaD
Vismodegib—Pain—Doxorubicin—sarcoma	7.25e-05	0.00151	CcSEcCtD
Vismodegib—Constipation—Doxorubicin—sarcoma	7.25e-05	0.00151	CcSEcCtD
Vismodegib—Abdominal pain—Epirubicin—sarcoma	7.25e-05	0.00151	CcSEcCtD
Vismodegib—SMO—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	7.14e-05	0.00368	CbGpPWpGaD
Vismodegib—SHH—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	7.11e-05	0.00367	CbGpPWpGaD
Vismodegib—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRB—sarcoma	7e-05	0.00361	CbGpPWpGaD
Vismodegib—Gastrointestinal pain—Doxorubicin—sarcoma	6.93e-05	0.00144	CcSEcCtD
Vismodegib—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRA—sarcoma	6.9e-05	0.00355	CbGpPWpGaD
Vismodegib—SHH—Disease—ENO2—sarcoma	6.77e-05	0.00349	CbGpPWpGaD
Vismodegib—SMO—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	6.74e-05	0.00348	CbGpPWpGaD
Vismodegib—Abdominal pain—Doxorubicin—sarcoma	6.7e-05	0.0014	CcSEcCtD
Vismodegib—Asthenia—Epirubicin—sarcoma	6.58e-05	0.00137	CcSEcCtD
Vismodegib—SHH—Signaling by GPCR—CXCR4—sarcoma	6.55e-05	0.00337	CbGpPWpGaD
Vismodegib—Pruritus—Epirubicin—sarcoma	6.48e-05	0.00135	CcSEcCtD
Vismodegib—ALB—FOXA2 and FOXA3 transcription factor networks—CREB1—sarcoma	6.33e-05	0.00326	CbGpPWpGaD
Vismodegib—SHH—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	6.32e-05	0.00326	CbGpPWpGaD
Vismodegib—Diarrhoea—Epirubicin—sarcoma	6.27e-05	0.0013	CcSEcCtD
Vismodegib—SMO—Signaling by GPCR—CXCR4—sarcoma	6.21e-05	0.0032	CbGpPWpGaD
Vismodegib—ABCG2—Fluoropyrimidine Activity—TP53—sarcoma	6.13e-05	0.00316	CbGpPWpGaD
Vismodegib—Asthenia—Doxorubicin—sarcoma	6.08e-05	0.00127	CcSEcCtD
Vismodegib—CYP3A4—Constitutive Androstane Receptor Pathway—FOXO1—sarcoma	6.08e-05	0.00313	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—TLE1—sarcoma	6.07e-05	0.00313	CbGpPWpGaD
Vismodegib—Pruritus—Doxorubicin—sarcoma	6e-05	0.00125	CcSEcCtD
Vismodegib—SMO—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	5.99e-05	0.00309	CbGpPWpGaD
Vismodegib—ABCB1—lymph node—sarcoma	5.85e-05	0.00127	CbGeAlD
Vismodegib—Vomiting—Epirubicin—sarcoma	5.83e-05	0.00121	CcSEcCtD
Vismodegib—Diarrhoea—Doxorubicin—sarcoma	5.8e-05	0.00121	CcSEcCtD
Vismodegib—Rash—Epirubicin—sarcoma	5.78e-05	0.0012	CcSEcCtD
Vismodegib—Dermatitis—Epirubicin—sarcoma	5.77e-05	0.0012	CcSEcCtD
Vismodegib—SMO—Signaling Pathways—TLE1—sarcoma	5.76e-05	0.00297	CbGpPWpGaD
Vismodegib—SHH—Disease—PLCG1—sarcoma	5.75e-05	0.00296	CbGpPWpGaD
Vismodegib—SHH—Disease—CXCR4—sarcoma	5.52e-05	0.00285	CbGpPWpGaD
Vismodegib—Nausea—Epirubicin—sarcoma	5.44e-05	0.00113	CcSEcCtD
Vismodegib—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—sarcoma	5.44e-05	0.0028	CbGpPWpGaD
Vismodegib—Vomiting—Doxorubicin—sarcoma	5.39e-05	0.00112	CcSEcCtD
Vismodegib—Rash—Doxorubicin—sarcoma	5.35e-05	0.00111	CcSEcCtD
Vismodegib—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—sarcoma	5.35e-05	0.00276	CbGpPWpGaD
Vismodegib—Dermatitis—Doxorubicin—sarcoma	5.34e-05	0.00111	CcSEcCtD
Vismodegib—ABCG2—HIF-1-alpha transcription factor network—JUN—sarcoma	5.33e-05	0.00275	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—VEGFC—sarcoma	5.12e-05	0.00264	CbGpPWpGaD
Vismodegib—Nausea—Doxorubicin—sarcoma	5.04e-05	0.00105	CcSEcCtD
Vismodegib—SMO—Signaling Pathways—VEGFC—sarcoma	4.86e-05	0.0025	CbGpPWpGaD
Vismodegib—ABCB1—Allograft Rejection—PDGFRA—sarcoma	4.71e-05	0.00243	CbGpPWpGaD
Vismodegib—ABCG2—HIF-1-alpha transcription factor network—VEGFA—sarcoma	4.66e-05	0.0024	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—sarcoma	4.38e-05	0.00226	CbGpPWpGaD
Vismodegib—ALB—Platelet activation, signaling and aggregation—VEGFC—sarcoma	4.3e-05	0.00222	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—FLT1—sarcoma	4.09e-05	0.00211	CbGpPWpGaD
Vismodegib—SHH—Disease—FOXO1—sarcoma	4.08e-05	0.0021	CbGpPWpGaD
Vismodegib—SHH—Disease—PDGFRB—sarcoma	4.07e-05	0.0021	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—PLCG1—sarcoma	4.02e-05	0.00207	CbGpPWpGaD
Vismodegib—ABCB1—HIF-1-alpha transcription factor network—CREB1—sarcoma	4.01e-05	0.00207	CbGpPWpGaD
Vismodegib—SHH—Disease—PDGFRA—sarcoma	4.01e-05	0.00207	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—FLT1—sarcoma	3.88e-05	0.002	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—CXCR4—sarcoma	3.87e-05	0.00199	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—ATF1—sarcoma	3.82e-05	0.00197	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—PLCG1—sarcoma	3.82e-05	0.00197	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—CXCR4—sarcoma	3.67e-05	0.00189	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—ATF1—sarcoma	3.62e-05	0.00187	CbGpPWpGaD
Vismodegib—SHH—Signaling by GPCR—CREB1—sarcoma	3.51e-05	0.00181	CbGpPWpGaD
Vismodegib—ALB—Folate Metabolism—IL2—sarcoma	3.38e-05	0.00174	CbGpPWpGaD
Vismodegib—SMO—Signaling by GPCR—CREB1—sarcoma	3.32e-05	0.00171	CbGpPWpGaD
Vismodegib—SHH—Disease—KIT—sarcoma	3.11e-05	0.0016	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—TEK—sarcoma	3.02e-05	0.00156	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—IGF1R—sarcoma	3e-05	0.00155	CbGpPWpGaD
Vismodegib—SHH—Disease—CREB1—sarcoma	2.96e-05	0.00152	CbGpPWpGaD
Vismodegib—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—sarcoma	2.94e-05	0.00152	CbGpPWpGaD
Vismodegib—ABCB1—HIF-1-alpha transcription factor network—JUN—sarcoma	2.88e-05	0.00149	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—FOXO1—sarcoma	2.86e-05	0.00147	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—PDGFRB—sarcoma	2.85e-05	0.00147	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—IGF1R—sarcoma	2.84e-05	0.00147	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—PDGFRA—sarcoma	2.81e-05	0.00145	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—ANGPT2—sarcoma	2.76e-05	0.00142	CbGpPWpGaD
Vismodegib—CYP3A4—Tryptophan metabolism—MDM2—sarcoma	2.73e-05	0.00141	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—FOXO1—sarcoma	2.71e-05	0.0014	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—PDGFRB—sarcoma	2.7e-05	0.00139	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—PDGFRA—sarcoma	2.66e-05	0.00137	CbGpPWpGaD
Vismodegib—SHH—Signaling by GPCR—IL2—sarcoma	2.59e-05	0.00134	CbGpPWpGaD
Vismodegib—ABCB1—Allograft Rejection—IL2—sarcoma	2.57e-05	0.00132	CbGpPWpGaD
Vismodegib—ABCB1—HIF-1-alpha transcription factor network—VEGFA—sarcoma	2.52e-05	0.0013	CbGpPWpGaD
Vismodegib—ALB—Platelet degranulation—VEGFA—sarcoma	2.47e-05	0.00127	CbGpPWpGaD
Vismodegib—SMO—Signaling by GPCR—IL2—sarcoma	2.46e-05	0.00127	CbGpPWpGaD
Vismodegib—SHH—Disease—MDM2—sarcoma	2.45e-05	0.00126	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—KDR—sarcoma	2.36e-05	0.00122	CbGpPWpGaD
Vismodegib—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—sarcoma	2.35e-05	0.00121	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	2.32e-05	0.0012	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—KDR—sarcoma	2.24e-05	0.00115	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—VEGFC—sarcoma	2.22e-05	0.00114	CbGpPWpGaD
Vismodegib—ABCB1—Allograft Rejection—VEGFA—sarcoma	2.18e-05	0.00112	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—KIT—sarcoma	2.18e-05	0.00112	CbGpPWpGaD
Vismodegib—SHH—Signaling by GPCR—NRAS—sarcoma	2.18e-05	0.00112	CbGpPWpGaD
Vismodegib—ALB—Folate Metabolism—TP53—sarcoma	2.17e-05	0.00112	CbGpPWpGaD
Vismodegib—SHH—Disease—CTNNB1—sarcoma	2.11e-05	0.00109	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—CREB1—sarcoma	2.07e-05	0.00107	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—KIT—sarcoma	2.06e-05	0.00106	CbGpPWpGaD
Vismodegib—SMO—Signaling by GPCR—NRAS—sarcoma	2.06e-05	0.00106	CbGpPWpGaD
Vismodegib—SHH—Signaling by GPCR—EGFR—sarcoma	1.98e-05	0.00102	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—CREB1—sarcoma	1.96e-05	0.00101	CbGpPWpGaD
Vismodegib—SHH—Disease—SRC—sarcoma	1.91e-05	0.000983	CbGpPWpGaD
Vismodegib—SMO—Signaling by GPCR—EGFR—sarcoma	1.88e-05	0.000969	CbGpPWpGaD
Vismodegib—SHH—Signaling by GPCR—KRAS—sarcoma	1.87e-05	0.000965	CbGpPWpGaD
Vismodegib—SHH—Disease—NRAS—sarcoma	1.84e-05	0.000946	CbGpPWpGaD
Vismodegib—SMO—Signaling by GPCR—KRAS—sarcoma	1.78e-05	0.000915	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—PLCG1—sarcoma	1.74e-05	0.000899	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	1.71e-05	0.000883	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—MDM2—sarcoma	1.71e-05	0.000883	CbGpPWpGaD
Vismodegib—SHH—Disease—MYC—sarcoma	1.71e-05	0.000881	CbGpPWpGaD
Vismodegib—SHH—Disease—EGFR—sarcoma	1.67e-05	0.000862	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—MDM2—sarcoma	1.62e-05	0.000837	CbGpPWpGaD
Vismodegib—SHH—Signaling by GPCR—HRAS—sarcoma	1.59e-05	0.00082	CbGpPWpGaD
Vismodegib—SHH—Disease—KRAS—sarcoma	1.58e-05	0.000814	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—IL2—sarcoma	1.53e-05	0.000789	CbGpPWpGaD
Vismodegib—SMO—Signaling by GPCR—HRAS—sarcoma	1.51e-05	0.000778	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—CCND1—sarcoma	1.49e-05	0.000769	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—JUN—sarcoma	1.49e-05	0.000768	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—CTNNB1—sarcoma	1.48e-05	0.000762	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—IL2—sarcoma	1.45e-05	0.000748	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	1.42e-05	0.000731	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—CCND1—sarcoma	1.42e-05	0.000729	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—JUN—sarcoma	1.41e-05	0.000728	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—CTNNB1—sarcoma	1.4e-05	0.000722	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—ENO2—sarcoma	1.35e-05	0.000696	CbGpPWpGaD
Vismodegib—SHH—Disease—HRAS—sarcoma	1.34e-05	0.000692	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—HBA1—sarcoma	1.34e-05	0.000691	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—SRC—sarcoma	1.34e-05	0.000689	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—VEGFA—sarcoma	1.3e-05	0.000671	CbGpPWpGaD
Vismodegib—ALB—Platelet activation, signaling and aggregation—IL2—sarcoma	1.29e-05	0.000663	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—NRAS—sarcoma	1.29e-05	0.000663	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—SRC—sarcoma	1.27e-05	0.000653	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	1.24e-05	0.000637	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—VEGFA—sarcoma	1.23e-05	0.000636	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	1.23e-05	0.000635	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	1.22e-05	0.00063	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—NRAS—sarcoma	1.22e-05	0.000628	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—MYC—sarcoma	1.2e-05	0.000617	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—EGFR—sarcoma	1.17e-05	0.000604	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—PLCG1—sarcoma	1.15e-05	0.00059	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—MYC—sarcoma	1.14e-05	0.000585	CbGpPWpGaD
Vismodegib—ALB—Platelet activation, signaling and aggregation—SRC—sarcoma	1.12e-05	0.000579	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—EGFR—sarcoma	1.11e-05	0.000572	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—KRAS—sarcoma	1.11e-05	0.00057	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	1.11e-05	0.00057	CbGpPWpGaD
Vismodegib—ALB—Platelet activation, signaling and aggregation—VEGFA—sarcoma	1.09e-05	0.000564	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	1.08e-05	0.000555	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—KRAS—sarcoma	1.05e-05	0.000541	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	9.91e-06	0.000511	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—TP53—sarcoma	9.83e-06	0.000507	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	9.69e-06	0.000499	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—HRAS—sarcoma	9.4e-06	0.000485	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—TP53—sarcoma	9.32e-06	0.00048	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	9.15e-06	0.000472	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—HRAS—sarcoma	8.92e-06	0.000459	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—ENO2—sarcoma	8.38e-06	0.000432	CbGpPWpGaD
Vismodegib—ALB—Metabolism—ENO2—sarcoma	8.33e-06	0.000429	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—HBA1—sarcoma	8.33e-06	0.000429	CbGpPWpGaD
Vismodegib—ALB—Metabolism—HBA1—sarcoma	8.28e-06	0.000427	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	8.14e-06	0.000419	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—ENO2—sarcoma	7.48e-06	0.000385	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—HBA1—sarcoma	7.43e-06	0.000383	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—ENO2—sarcoma	7.3e-06	0.000376	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—HBA1—sarcoma	7.25e-06	0.000374	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—PLCG1—sarcoma	7.11e-06	0.000366	CbGpPWpGaD
Vismodegib—ALB—Metabolism—PLCG1—sarcoma	7.07e-06	0.000364	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—ENO2—sarcoma	6.82e-06	0.000351	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—HBA1—sarcoma	6.78e-06	0.000349	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—IL2—sarcoma	6.63e-06	0.000342	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—PLCG1—sarcoma	6.35e-06	0.000327	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—PLCG1—sarcoma	6.19e-06	0.000319	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—SRC—sarcoma	5.79e-06	0.000298	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—PLCG1—sarcoma	5.79e-06	0.000298	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—VEGFA—sarcoma	5.64e-06	0.000291	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—NRAS—sarcoma	5.57e-06	0.000287	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—KRAS—sarcoma	4.79e-06	0.000247	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—ENO2—sarcoma	4.5e-06	0.000232	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—HBA1—sarcoma	4.47e-06	0.00023	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—TP53—sarcoma	4.26e-06	0.00022	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—HRAS—sarcoma	4.07e-06	0.00021	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—PLCG1—sarcoma	3.82e-06	0.000197	CbGpPWpGaD
